52 SUNDAY • MAY 15 P60 P61 Facilitator: P62 P63 P64 P65 P66 of Desloratadine in Japanese Patients with Seasonal Allergic Rhinitis/S. Hisada, Y. Maeda, N. Oshima, Y. Tanaka, C.I. Weinstein, K. Okubo, Tokyo, Japan, p.A1393 Clinical Implication of Adenosine Triphosphate in Sputum in Asthma/T. Soma, T. Kobayashi, K. Nakagome, M. Nagata, Saitama, Japan, p.A1394 Functional Antibody Deficiency in Chronic Lung Disease/R.M. Trafford, V. Moffat, T. Brockley, C. Pantin, M. Babores, S. Iyer, Macclesfield, United Kingdom, p.A1395 A. Yokoyama, MD, PhD, Kochi, Japan Responder Rate Analysis of Asthma Control Questionnaire Scores in Patients Treated with Once-Daily Fluticasone Furoate/ Vilanterol or Fluticasone Furoate/C. Poor, S. Faison, L. Sutton, D. Stempel, Research Triangle Park, NC, p.A1396 Impact of Irreversible Airflow Obstruction in Clinical Course of Patients with Severe Atopic Asthma/K. Orimo, K. Takeyama, E. Tagaya, M. Kondo, J. Tamaoki, Tokyo, Japan, p.A1397 Exploring Asthma Patients for Whom Switching to Formoterol/Fluticasone Is Recommendable Among Patients Inadequately Controlled with Salmeterol/Fluticasone/T. Kamei, K. Kato, H. Mizutani, M. Hayashi, N. Kihara, Takamatsu, Japan, p.A1398 Development of a Questionnaire to Evaluate Asthma Control in Japanese Asthma Patients: A Pilot Study/S. Hozawa, H. Tanaka, F. Mori, Y. Tohda, Hiroshima, Japan, p.A1399 Short-Term Effectiveness of Bronchial Thermoplasty on Quality of Life and Control in Patients with Severe Asthma/K. Kobayashi, M. Iikura, A. Shiozawa, I. Takazawa, S. Yamamoto, H. Kawamoto, S. Ro, S. Ishii, S. Izumi, M. Hojo, H. Sugiyama, Tokyo, Japan, p.A1400 P67 Does Asthma Phenotype Have Impact on Disease Control - Can Detection of Inflammation and Hyperresponsiveness Ensure Stable Disease Faster (APERITIF)?/K.F. Bernholm, A.-S., Homøe, H. Meteran, C. Porsbjerg, V. Backer, Copenhagen, Denmark, p.A1401 P68 P69 P70 Facilitator: P71 P72 Optimal Sampling Designs for Studies of Multiple Flow Exhaled Nitric Oxide/S.P. Eckel, N. Molshatski, Los Angeles, CA, p.A1402 Allergic Bronchopulmonary Aspergillosis in South Asia with Special Reference to Indian Children: The Demographic and Clinical Presentation/M. Singh, N. Paul, A. Chauhan, K.S. Sodhi, A. Chakrabarti, Chandigarh, India, p.A1403 Prevalence of Allergic Diseases in Children Living in Rural and Urban Areas in Turkey/Y. Gokdemir, E. Civelek, B. Cakir, A. Demir, C.N. Kocabas, R. Ersu, Istanbul, Turkey, p.A1404 J.G. Zein, MD, Cleveland, OH Reduction in FeNO Is Correlated with FEV1 Improvement in Lebrikizumab Treated Asthma Patients/F. Cai, Y. Zheng, C. Holweg, D. Choy, J. Olsson, J. Matthews, H. Schereens, South San Francisco, CA, p.A1405 Efficacy and Safety of Tratinterol Hydrochloride Tablets in Bronchial Asthma: A Randomized, Double-Blind and Multicenter Clinical Trial/L. Kong, J. Kang, Y. Zhao, Shenyang, China, p.A1406 P73 P74 P75 P76 P77 P78 P79 P80 P81 A37 Clinical Effectiveness of Omalizumab in Severe Allergic Asthma Above the Recommended Dosing Range: The Australian Xolair Registry/M. Hew, A. Gillman, M. Sutherland, P. Wark, J. Bowden, V. McDonald, M. Guo, H. Reddel, C. Jenkins, G. Marks, J. Upham, F. Thien, J. Rimmer, G.P. Katsoulotos, M. Cook, I. Yang, C. Katelaris, S. Bowler, D. Langton, P.G. Gibson, P.D. Robinson, C. Wright, M. Bint, V. Yozghatlian, S. Burgess, P. Sivakumaran, A. Jaffe, K. Yan, M. Peters, V. Kritikos, M. Baraket, A. Aminazad, Melbourne, Australia, p.A1408 A Phase IIb Dose-Finding Study to Assess the Efficacy and Safety of QAW039 (Fevipiprant) in Patients with Allergic Asthma Uncontrolled on Low-Dose ICS Therapy/E.D. Bateman, A.M. Mesquita, A.G. Guerreros, F. Brockhaus, B. Holzhauer, A. Pethe, R.A. Kay, R.G. Townley, Cape Town, South Africa, p.A1408 Airway Eosinophilic Inflammation Assessed by Induced Sputum and Blood IgE In Asthmatic Children/M. Ghezzi, A. Kantar, Ponte San Pietro, Italy, p.A1409 The Effects of Low- and High- Expression of Brain-Derived Neurotrophic Factor on the Intensity of Psychopathological Variables in Asthma Patients: A Preliminary Report/M.G. Panek, J. Ziolo, M. Jonakowski, T. Pietras, A. Antczak, J. Szemraj, P. Kuna, Lodz, Poland, p.A1410 Reduction of Systemic Corticosteroid Requirement for Severe Asthma Following Minimally-Invasive Nissen Fundoplication for Severe GERD/S. Patel, A.K. Mathur, C. Galvani, T.F. Carr, Tucson, AZ, p.A1411 House Dust Mite Sensitization as a Risk Factor for Exacerbation of Asthma in the Fall/H.H. Kim, J.-S. Yoon, Y.H. Chun, H.S. Kim, Uijeongbu-si, Gyeonggi-do, Korea, Republic of, p.A1412 Gender-Specific Effect of Overweight and Obesity on Total Serum IgE in Adults with Allergic Asthma/M. Imaoka, Fukuoka, Japan, p.A7776 The Potential Association between Adipocytokine and Steroid Insensitivity in Obese Asthmatic Patients/M. To, N. Ogura, S. Mikami, S. Soeda, H. Hara, N. Honda, A. Hitani, I. Kano, K. Haruki, Y. To, Saitama, Japan, p.A7777 Clinical Characteristics of Obese Asthmatic Patients: Obese Asthmatic Patients Need More Frequent Unscheduled Visits and Rescue Uses of Corticosteroids/M. To, N. Ogura, S. Mikami, S. Soeda, H. Hara, N. Honda, A. Hitani, I. Kano, K. Haruki, Y. To, Saitama, Japan, p.A7778 THEMATIC POSTER SESSION CYSTIC FIBROSIS: IMMUNE REGULATORY PATHWAYS 9:00 a.m. - 4:15 p.m. MOSCONE CENTER Viewing: Posters will be on display for entire session. Area G, Hall D (North Building, Lower Level) Discussion: 11:00-11:45: authors will be present for individual discussion 11:45-12:45: authors will be present for discussion with assigned facilitators ATS 2016 • San Francisco
SUNDAY • MAY 15 53 Facilitator: P715 P716 P717 P718 P719 P720 A38 B.M. Morrissey, MD, Sacramento, CA PB01: A Recombinant Human Follistatin Protein for the Treatment of Neutrophilic Lung Diseases/B.M. Kita, C.L. Hardy, R.E. O’Hehir, M. Hedger, D.M. De Kretser, Caulfield North, Australia, p.A1413 CF Airway Epithelia Contribute to the Compromised Innate Immunity Against Bacterial Infection/X. Yang, V. Patel, M. Wang, D.D. Thomas, L.L. Mantell, Jamaica, NY, p.A1414 Altered Phagosomal Degranulation in Neutrophils of Individuals with Cystic Fibrosis; an Impairment Corrected by CFTR Potential Therapy/N. Browne, F. Gargoum, P. Hawkins, E. Reeves, N.G. McElvaney, Dublin, Ireland, p.A1415 Use of the Basophil Surface Marker CD203c in the Identification of Aspergillus Fumigatus Sensitisation in Cystic Fibrosis/G.M. Lavelle, B. Mirkovic, A.A. Azim, K. Helma, F. Gargoum, K. Molloy, Y. Gernez, K. Dunne, J. Renwick, P. Murphy, C.M. Greene, R.B. Moss, C. Gunaratnam, S.H. Chotirmall, N.G. McElvaney, Dublin, Ireland, p.A1416 The Metalloprotease LasB from Pseudomonas Aeruginosa Subverts Innate Immunity In Vitro and In Vivo/J.-M. Sallenave, V. Saint-Criq, F. Bastaert, B. Villeret, A. Hatton, A. Edelman, Paris, France, p.A1417 Electrolyte Transport Properties in Distal Small Airways from Cystic Fibrosis Pigs with Implications for Host Defense/X. Li, X.X. Tang, L.G. Vargas Buonfiglio, P. Karp, P. Taft, K. Sheets, M. Welsh, D. Stoltz, J. Zabner, Coralville, IA, p.A1418 THEMATIC POSTER SESSION DIAGNOSTIC MARKERS OF ASTHMA AND COPD 9:00 a.m. - 4:15 p.m. MOSCONE CENTER Viewing: Posters will be on display for entire session. Area B, Hall D (North Building, Lower Level) Discussion: 11:00-11:45: authors will be present for individual discussion 11:45-12:45: authors will be present for discussion with assigned facilitators Facilitator: P135 P136 P137 M.R. Stampfli, PhD, Hamilton, Canada Cluster Analysis of Asthma Patients with Allergic Rhinitis Including Rhinitis Symptoms and Serum Periostin Levels as Variable/N. Sugimoto, H. Nagase, M. Kinoshita, H. Sakasegawa, T. Esaki, M. Ohsumi, Y. Koizumi, Y. Tanaka, S. Ro, H. Yoshihara, M. Kuramochi, H. Arai, M. Yamaguchi, K. Izuhara, K. Ohta, Tokyo, Japan, p.A1419 Reference Ranges for Serum Periostin in a Population Without Asthma or COPD/I. Braithwaite, R. Caswell-Smith, A. Hosking, T. Cripps, C. Holweg, J. Matthews, M. Holliday, C. Maillot, J. Fingleton, M. Weatherall, R. Beasley, Wellington, New Zealand, p.A1420 Sinus Computed Tomographic Findings in Smoking and Non-Smoking Asthmatics: Associations with Asthma-Related Indices and Biomarkers Analysis/H. Kimura, S. Konno, Y. Nakamaru, H. Makita, N. Taniguchi, K. Shimizu, M. Suzuki, J. Ono, K. Izuhara, M. Nishimura, Sapporo, Japan, p.A1421 P138 P139 P140 P141 P142 Facilitator: P143 P144 P145 P146 P147 P148 Multi-Level Differential Network Analysis of COPD Exacerbations/R. Faner, G. Noell, B.G. Cosio, T. Casserras, I. Coca, E. Monso, G. Peces-Barba, A. De Diego, C. Esteban, J. Gea, S. Kalko, A. Agusti, Barcelona, Spain, p.A1422 The Relative Importance of av-Integrins in Chronic Obstructive Pulmonary Disease/C. Moermans, H. Lou, O.J. Brand, A. Cormier, A. Bondesson, P.J. Wolters, D. Jablons, L. Murray, S. Nishimura, San Francisco, CA, p.A1423 Discovery of Non-Invasive Biomarkers of IL-17 Activity from Experimental Models of Asthma/M. Bremer, D. Choy, G. Jia, D. Nagarkar, S. Kotwal, W. Lee, A. Abbas, F. Cai, J. Arron, H. Scheerens, T. Staton, South San Francisco, CA, p.A1424 Different Pathways of Inflammasome Activation in Human Precision-Cut Lung Slices (PCLS)/S. Konzok, P. Braubach, D. Peter, D. Jonigk, H.-G. Fieguth, A. Braun, K. Sewald, Hannover, Germany, p.A1425 Biomarker Characterization of a Debilitated Phenotype in SPIROMICS/I. Barjaktarevic, C.H. Martinez, J.L. Curtis, R.P. Bowler, W.K. O'Neal, E.A. Hoffman, E.E. Carretta, M. Quibrera, R.G. Barr, E. Bleecker, D.J. Couper, G.J. Criner, M.T. Dransfield, M.K. Han, N.N. Hansel, R. Kanner, S.C. Lazarus, F.J. Martinez, R. Paine, III, D.P. Tashkin, P.G. Woodruff, C.B. Cooper, Los Angeles, CA, p.A1426 S.M. Lyon, MD, Philadelphia, PA Cigarette Smoke and Cigarette Smoke Condensate Induce Early Biomarkers of Inflammation and Cytotoxicity in Precision-Cut Lung Slices/H. Obernolte, D. Ritter, J.W. Knebel, P. Braubach, D. Jonigk, H.-G. Fieguth, A. Braun, K. Sewald, Hannover, Germany, p.A1427 Evaluation of Th2 and Th17 Cytokine Levels in Serum from Asthmatics Using the High Sensitivity Quanterix Simoa HD-1 Platform/M.L. Gavala, D. Smith, South San Francisco, CA, p.A1428 Airway Inflammation and Clinical Manifestations in Patients with Mild Asthma: Time Course of Human Rhinovirus (HRV) Induced Changes/J. Efthimiou, A. Mann, G. Balaratnam, J. Gunter, P. Rucki, C. Poll, M. Johnson, T. Lockett, London, United Kingdom, p.A1429 What Are the Priorities for Future Research into Diagnostic Tools for Asthma? A Pan-EU Consensus Exercise/L. Garcia-Marcos, J.L. Edwards, E.J. Kennington, S. Walker, Murcia, Spain, p.A1430 Multidimensional Analysis of Human Lung Myeloid Cells Reveal Unique Subpopulations in COPD and IPF/J.J. Atkinson, B.C. Keller, D.G. Kelley, X. Jin, R.M. Senior, R.M. Presti, D.E. Byers, St. Louis, MO, p.A1431 Current Smoking Increases Macrophage Numbers and Immunoregulatory Receptor Expression in Bronchoalveolar Lavage but not Sputum in Chronic Obstructive Pulmonary Disease: SPIROMICS Immunophenotyping Sub-Study/ J.P. Brown, C.M. Freeman, S.W. Crudgington, V.R. Stolberg, J. Sonstein, N.E. Alexis, P.V. Basta, E.E. Carretta, S. Christenson, D.J. Couper, C.M. Doerschuk, N.N. Hansel, M.K. Han, A.T. Hastie, R.J. Kaner, F.J. Martinez, W.K. O'Neal, R. Paine, III, S.I. Rennard, D. Shimbo, P.G. Woodruff, M. Zeidler, J.L. Curtis, Ann Arbor, MI, p.A1432 SUNDAY MORNING ATS 2016 • San Francisco
- Page 1 and 2:
American Thoracic Society Internati
- Page 3:
TABLE OF CONTENTS ATS 2016 INTERNAT
- Page 6 and 7: 2 FRIDAY • MAY 13 PG2A CLINICAL P
- Page 8 and 9: 4 FRIDAY • MAY 13 Target Audience
- Page 10 and 11: 6 FRIDAY • MAY 13 11:15 Case Disc
- Page 12 and 13: 8 FRIDAY • MAY 13 Chairing: H.B.
- Page 14 and 15: 10 FRIDAY • MAY 13 10:25 Advanced
- Page 16 and 17: 12 FRIDAY • MAY 13 Objectives At
- Page 18 and 19: 14 SATURDAY • MAY 14 Abdominal Ul
- Page 20 and 21: 16 SATURDAY • MAY 14 PG17 BASIC
- Page 22 and 23: 18 SATURDAY • MAY 14 1:05 In What
- Page 24 and 25: 20 SATURDAY • MAY 14 10:30 Practi
- Page 26 and 27: 22 SATURDAY • MAY 14 Objectives A
- Page 28 and 29: 24 SATURDAY • MAY 14 10:10 Is My
- Page 30 and 31: 26 SUNDAY • MAY 15 Chairing: D.M.
- Page 32 and 33: 28 SUNDAY • MAY 15 Chronic Cough:
- Page 34 and 35: 30 SUNDAY • MAY 15 • understand
- Page 36 and 37: 32 SUNDAY • MAY 15 Target Audienc
- Page 38 and 39: 34 SUNDAY • MAY 15 Oral Presentat
- Page 40 and 41: 36 SUNDAY • MAY 15 9:15 Hyperpola
- Page 42 and 43: 38 SUNDAY • MAY 15 310 A Smartpho
- Page 44 and 45: 40 SUNDAY • MAY 15 103 Immunosupp
- Page 46 and 47: 42 SUNDAY • MAY 15 A26 POSTER DIS
- Page 48 and 49: 44 SUNDAY • MAY 15 822 Incidence
- Page 50 and 51: 46 SUNDAY • MAY 15 519 Maternal H
- Page 52 and 53: 48 SUNDAY • MAY 15 P14 P15 P16 P1
- Page 54 and 55: 50 SUNDAY • MAY 15 P1545 P1546 Fa
- Page 58 and 59: 54 SUNDAY • MAY 15 P149 P150 Faci
- Page 60 and 61: 56 SUNDAY • MAY 15 P749 P750 P751
- Page 62 and 63: 58 SUNDAY • MAY 15 Facilitator: P
- Page 64 and 65: 60 SUNDAY • MAY 15 P1243 P1244 P1
- Page 66 and 67: 62 SUNDAY • MAY 15 P1295 P1296 P1
- Page 68 and 69: 64 SUNDAY • MAY 15 P1358 P1359 P1
- Page 70 and 71: 66 SUNDAY • MAY 15 P91 Facilitato
- Page 72 and 73: 68 SUNDAY • MAY 15 P616 P617 P618
- Page 74 and 75: 70 SUNDAY • MAY 15 P914 P915 P916
- Page 76 and 77: 72 SUNDAY • MAY 15 P556 P557 P558
- Page 78 and 79: 74 SUNDAY • MAY 15 Facilitators:
- Page 80 and 81: 76 SUNDAY • MAY 15 P997 P998 P999
- Page 82 and 83: 78 SUNDAY • MAY 15 P256 P257 P258
- Page 84 and 85: 80 SUNDAY • MAY 15 A61 THEMATIC P
- Page 86 and 87: 82 SUNDAY • MAY 15 P824 Facilitat
- Page 88 and 89: 84 SUNDAY • MAY 15 P1055 P1056 P1
- Page 90 and 91: 86 SUNDAY • MAY 15 P1101 P1102 P1
- Page 92 and 93: 88 SUNDAY • MAY 15 P1423 P1424 P1
- Page 94 and 95: 90 SUNDAY • MAY 15 P1474 P1475 P1
- Page 96 and 97: 92 SUNDAY • MAY 15 P377 P378 P379
- Page 98 and 99: 94 SUNDAY • MAY 15 P281 P282 P283
- Page 100 and 101: 96 SUNDAY • MAY 15 P450 P451 A74
- Page 102 and 103: 98 SUNDAY • MAY 15 P1562 P1563 P1
- Page 104 and 105: 100 SUNDAY • MAY 15 A80-A THEMATI
- Page 106 and 107:
102 SUNDAY • MAY 15 Facilitator:
- Page 108 and 109:
104 SUNDAY • MAY 15 11:00 a.m.-12
- Page 110 and 111:
106 SUNDAY • MAY 15 L1 U.S. FOOD
- Page 112 and 113:
108 SUNDAY • MAY 15 12:15 Post-Pr
- Page 114 and 115:
110 SUNDAY • MAY 15 MP406 MP407 M
- Page 116 and 117:
112 SUNDAY • MAY 15 clinician and
- Page 118 and 119:
114 SUNDAY • MAY 15 A86 BASIC •
- Page 120 and 121:
116 SUNDAY • MAY 15 Chairing: M.J
- Page 122 and 123:
118 SUNDAY • MAY 15 3:30 High Pre
- Page 124 and 125:
120 SUNDAY • MAY 15 102 Toll-Like
- Page 126 and 127:
122 SUNDAY • MAY 15 A103 POSTER D
- Page 128 and 129:
124 SUNDAY • MAY 15 719 Lactate R
- Page 130 and 131:
126 SUNDAY • MAY 15 1014 Determin
- Page 132 and 133:
128 SUNDAY • MAY 15 611 Plasma Mi
- Page 134 and 135:
130 SUNDAY • MAY 15 412 Daytime S
- Page 136 and 137:
132 SUNDAY • MAY 15 6:30 p.m. - 8
- Page 138 and 139:
134 MONDAY • MAY 16 SS111 SS112 S
- Page 140 and 141:
136 MONDAY • MAY 16 Target Audien
- Page 142 and 143:
138 MONDAY • MAY 16 9:40 Empoweri
- Page 144 and 145:
140 MONDAY • MAY 16 9:28 Endotoxi
- Page 146 and 147:
142 MONDAY • MAY 16 10:15 Adaptiv
- Page 148 and 149:
144 MONDAY • MAY 16 Oral Presenta
- Page 150 and 151:
146 MONDAY • MAY 16 624 Neonatal
- Page 152 and 153:
148 MONDAY • MAY 16 118 Compariso
- Page 154 and 155:
150 MONDAY • MAY 16 912 Should Pa
- Page 156 and 157:
152 MONDAY • MAY 16 1015 Resverat
- Page 158 and 159:
154 MONDAY • MAY 16 718 Health Re
- Page 160 and 161:
156 MONDAY • MAY 16 P152 Facilita
- Page 162 and 163:
158 MONDAY • MAY 16 B35 THEMATIC
- Page 164 and 165:
160 MONDAY • MAY 16 P252 P253 P25
- Page 166 and 167:
162 MONDAY • MAY 16 P406 P407 P40
- Page 168 and 169:
164 MONDAY • MAY 16 P320 Bilatera
- Page 170 and 171:
166 MONDAY • MAY 16 B40 THEMATIC
- Page 172 and 173:
168 MONDAY • MAY 16 P528 P529 Fac
- Page 174 and 175:
170 MONDAY • MAY 16 Facilitator:
- Page 176 and 177:
172 MONDAY • MAY 16 B44 THEMATIC
- Page 178 and 179:
174 MONDAY • MAY 16 P484 P485 P48
- Page 180 and 181:
176 MONDAY • MAY 16 P1161 P1162 P
- Page 182 and 183:
178 MONDAY • MAY 16 B48 THEMATIC
- Page 184 and 185:
180 MONDAY • MAY 16 P1238 P1239 P
- Page 186 and 187:
182 MONDAY • MAY 16 P1297 P1298 P
- Page 188 and 189:
184 MONDAY • MAY 16 Facilitator:
- Page 190 and 191:
186 MONDAY • MAY 16 P15 P16 P17 P
- Page 192 and 193:
188 MONDAY • MAY 16 Facilitator:
- Page 194 and 195:
190 MONDAY • MAY 16 P114 P115 P11
- Page 196 and 197:
192 MONDAY • MAY 16 P1408 Enhance
- Page 198 and 199:
194 MONDAY • MAY 16 P1455 P1456 P
- Page 200 and 201:
196 MONDAY • MAY 16 P1487 P1488 P
- Page 202 and 203:
198 MONDAY • MAY 16 P1514 P1515 P
- Page 204 and 205:
200 MONDAY • MAY 16 Facilitator:
- Page 206 and 207:
202 MONDAY • MAY 16 P559 P560 P56
- Page 208 and 209:
204 MONDAY • MAY 16 WS3 CLINICAL
- Page 210 and 211:
206 MONDAY • MAY 16 Satellite ear
- Page 212 and 213:
208 MONDAY • MAY 16 Objectives At
- Page 214 and 215:
210 MONDAY • MAY 16 encourage tra
- Page 216 and 217:
212 MONDAY • MAY 16 B82 BEHAVIORA
- Page 218 and 219:
214 MONDAY • MAY 16 B86 BASIC •
- Page 220 and 221:
216 MONDAY • MAY 16 and a number
- Page 222 and 223:
218 MONDAY • MAY 16 2:30 Mortalit
- Page 224 and 225:
220 MONDAY • MAY 16 3:00 Simultan
- Page 226 and 227:
222 MONDAY • MAY 16 525 Clinical
- Page 228 and 229:
224 MONDAY • MAY 16 320 Sensitivi
- Page 230 and 231:
226 MONDAY • MAY 16 113 COPD Subt
- Page 232 and 233:
228 MONDAY • MAY 16 1004 Health C
- Page 234 and 235:
230 MONDAY • MAY 16 609 Skeletal
- Page 236 and 237:
232 MONDAY • MAY 16 5:00 p.m. - 7
- Page 238 and 239:
234 TUESDAY • MAY 17 Chairing: D.
- Page 240 and 241:
236 TUESDAY • MAY 17 CLINICAL YEA
- Page 242 and 243:
238 TUESDAY • MAY 17 This session
- Page 244 and 245:
240 TUESDAY • MAY 17 bronchiectas
- Page 246 and 247:
242 TUESDAY • MAY 17 Target Audie
- Page 248 and 249:
244 TUESDAY • MAY 17 C18 MINI SYM
- Page 250 and 251:
246 TUESDAY • MAY 17 415 Investig
- Page 252 and 253:
248 TUESDAY • MAY 17 207 Survival
- Page 254 and 255:
250 TUESDAY • MAY 17 906 Phenotyp
- Page 256 and 257:
252 TUESDAY • MAY 17 807 The Vali
- Page 258 and 259:
254 TUESDAY • MAY 17 515 Roles of
- Page 260 and 261:
256 TUESDAY • MAY 17 P383 P384 P3
- Page 262 and 263:
258 TUESDAY • MAY 17 Facilitator:
- Page 264 and 265:
260 TUESDAY • MAY 17 P199 P200 P2
- Page 266 and 267:
262 TUESDAY • MAY 17 P620 Facilit
- Page 268 and 269:
264 TUESDAY • MAY 17 P428 P429 P4
- Page 270 and 271:
266 TUESDAY • MAY 17 P442 P443 P4
- Page 272 and 273:
268 TUESDAY • MAY 17 P318 P319 P3
- Page 274 and 275:
270 TUESDAY • MAY 17 P474 P475 Fa
- Page 276 and 277:
272 TUESDAY • MAY 17 Facilitator:
- Page 278 and 279:
274 TUESDAY • MAY 17 P727 P728 P7
- Page 280 and 281:
276 TUESDAY • MAY 17 P774 P775 Fa
- Page 282 and 283:
278 TUESDAY • MAY 17 C53 THEMATIC
- Page 284 and 285:
280 TUESDAY • MAY 17 C55 THEMATIC
- Page 286 and 287:
282 TUESDAY • MAY 17 P1095 P1096
- Page 288 and 289:
284 TUESDAY • MAY 17 P1167 P1168
- Page 290 and 291:
286 TUESDAY • MAY 17 P632 P633 P6
- Page 292 and 293:
288 TUESDAY • MAY 17 P546 P547 P5
- Page 294 and 295:
290 TUESDAY • MAY 17 Facilitator:
- Page 296 and 297:
292 TUESDAY • MAY 17 C65 THEMATIC
- Page 298 and 299:
294 TUESDAY • MAY 17 P659 P660 P6
- Page 300 and 301:
296 TUESDAY • MAY 17 P1506 P1507
- Page 302 and 303:
298 TUESDAY • MAY 17 C70 THEMATIC
- Page 304 and 305:
300 TUESDAY • MAY 17 P1363 P1364
- Page 306 and 307:
302 TUESDAY • MAY 17 P928 P929 P9
- Page 308 and 309:
304 TUESDAY • MAY 17 P973 P974 Fa
- Page 310 and 311:
306 TUESDAY • MAY 17 Facilitator:
- Page 312 and 313:
308 TUESDAY • MAY 17 C80 THEMATIC
- Page 314 and 315:
310 TUESDAY • MAY 17 P98 P99 P100
- Page 316 and 317:
312 TUESDAY • MAY 17 • become a
- Page 318 and 319:
314 TUESDAY • MAY 17 The topics a
- Page 320 and 321:
316 TUESDAY • MAY 17 C85 BASIC
- Page 322 and 323:
318 TUESDAY • MAY 17 C89 BASIC
- Page 324 and 325:
320 TUESDAY • MAY 17 3:20 Pediatr
- Page 326 and 327:
322 TUESDAY • MAY 17 2:45 Long-Te
- Page 328 and 329:
324 TUESDAY • MAY 17 918 Sarcoido
- Page 330 and 331:
326 TUESDAY • MAY 17 410 Effectiv
- Page 332 and 333:
328 TUESDAY • MAY 17 710 Follista
- Page 334 and 335:
330 TUESDAY • MAY 17 509 A Mechan
- Page 336 and 337:
332 TUESDAY • MAY 17 806 Upper Ai
- Page 338 and 339:
334 WEDNESDAY • MAY 18 6:45 Acute
- Page 340 and 341:
336 WEDNESDAY • MAY 18 CLINICAL Y
- Page 342 and 343:
338 WEDNESDAY • MAY 18 Objectives
- Page 344 and 345:
340 WEDNESDAY • MAY 18 D9 BASIC
- Page 346 and 347:
342 WEDNESDAY • MAY 18 Oral Prese
- Page 348 and 349:
344 WEDNESDAY • MAY 18 10:15 Plas
- Page 350 and 351:
346 WEDNESDAY • MAY 18 419 A Nove
- Page 352 and 353:
348 WEDNESDAY • MAY 18 216 Simpli
- Page 354 and 355:
350 WEDNESDAY • MAY 18 815 Multip
- Page 356 and 357:
352 WEDNESDAY • MAY 18 D28 POSTER
- Page 358 and 359:
354 WEDNESDAY • MAY 18 720 Repeat
- Page 360 and 361:
356 WEDNESDAY • MAY 18 P389 Facil
- Page 362 and 363:
358 WEDNESDAY • MAY 18 P439 P440
- Page 364 and 365:
360 WEDNESDAY • MAY 18 P10 P11 P1
- Page 366 and 367:
362 WEDNESDAY • MAY 18 P52 P53 Fa
- Page 368 and 369:
364 WEDNESDAY • MAY 18 P95 P96 P9
- Page 370 and 371:
366 WEDNESDAY • MAY 18 P698 P699
- Page 372 and 373:
368 WEDNESDAY • MAY 18 D42 THEMAT
- Page 374 and 375:
370 WEDNESDAY • MAY 18 P748 Funge
- Page 376 and 377:
372 WEDNESDAY • MAY 18 P353 P354
- Page 378 and 379:
374 WEDNESDAY • MAY 18 P172 P173
- Page 380 and 381:
376 WEDNESDAY • MAY 18 P808 Facil
- Page 382 and 383:
378 WEDNESDAY • MAY 18 P526 P527
- Page 384 and 385:
380 WEDNESDAY • MAY 18 P579 P580
- Page 386 and 387:
382 WEDNESDAY • MAY 18 P944 P945
- Page 388 and 389:
384 WEDNESDAY • MAY 18 P991 P992
- Page 390 and 391:
386 WEDNESDAY • MAY 18 P1036 P103
- Page 392 and 393:
388 WEDNESDAY • MAY 18 P1062 P106
- Page 394 and 395:
390 WEDNESDAY • MAY 18 11:45 Intr
- Page 396 and 397:
392 WEDNESDAY • MAY 18 12:15 Upda
- Page 398 and 399:
394 WEDNESDAY • MAY 18 This sessi
- Page 400 and 401:
396 WEDNESDAY • MAY 18 1:30 The B
- Page 402 and 403:
398 WEDNESDAY • MAY 18 D88 BEHAVI
- Page 404 and 405:
400 WEDNESDAY • MAY 18 3:00 Accel
- Page 406 and 407:
402 WEDNESDAY • MAY 18 D96 MINI S
- Page 408 and 409:
404 WEDNESDAY • MAY 18 604 CARMA3
- Page 410 and 411:
406 WEDNESDAY • MAY 18 702 Potent
- Page 412 and 413:
408 WEDNESDAY • MAY 18 803 ICU Ac
- Page 414 and 415:
410 WEDNESDAY • MAY 18 Chairing:
- Page 416 and 417:
412 WEDNESDAY • MAY 18 404 Interm
- Page 418:
Where today’s science meets tomor